GP’s have been banned from prescribing a number of higher cost diabetes drugs such as Byetta, Victoza, Januvia and Galvus .
A survey carried out by medical news provider, Pulse, under the Freedom of Information Act reveals more than fifty per cent of Primary Care Organisations (PCOs) have drawn blacklists of NICE approved drugs. 134 PCOs were quizzed and, of these, 73 had placed drugs on blacklists or put alternative restrictions on how these drugs could be prescribed.
A number of commonly prescribed and effective type 2 diabetes drugs have been included within the blacklists including: Byetta (Exenatide), Victoza (Liraglutide), Januvia (Sitagliptin), Galvus (Vildagliptin). Patients receiving these treatments tend to be those who have not responded well to cheaper alternatives or because cheaper medicines have promoted particular side effects, such as weight gain .
The news which broke on 12 April is a concern for patients currently taking these medicines and raises questions as to whether a tightening postcode lottery could see diabetic patients being moved on to cheaper alternative treatments, with more dangerous side effects, such as insulin .
Other drugs to have been blacklisted by some PCOs include the more expensive statins such as Lipitor (Atorvastatin) and Crestor (Rosuvastatin) as well as treatments for high blood pressure, pain relief and sexual dysfunction .
Rob49 said:I went to my MP who passed this troubling report onto Lord Howe, the Parliamentary Under Secretary of State at the Department of Health. His response was very positive. I will paraphrase it below as all I have is a scanned copy of this letter
Our Policy is that clinicians acting within the scope of their of their clinical competence should be able to prescribe medicines in line with NICE guidance. I believe there may be some confusion in terminology : many PCT's develop lists of medicines that should be initiated by specialists rather than GP's. If we have evidence that any PCT is not following our policy then my advice is to take the matter directly to the CEO of the PCT. If the situation is not resolved then the matter should be escalated to the relevant Strategic Health Authority, which can involve the Department of Health
(the letter is signed) Earl Howe
I think this answers the question and I would be happy to provide a copy the letter to anyone who needs it
Robin Frowd
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?